2021年胰腺神经内分泌肿瘤诊治的新进展

高鹤丽; 徐近; 虞先濬

doi:10.19401/j.cnki.1007-3639.2022.09.003

您当前的位置：

首页 >

文章列表页 >

2021年胰腺神经内分泌肿瘤诊治的新进展

专家述评 | 更新时间：2025-12-31

- 2021年胰腺神经内分泌肿瘤诊治的新进展
- Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021
- 中国癌症杂志 2022年32卷第9期页码：772-778
- 作者机构：
  
  复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032
- 作者简介：
  
  [ "高鹤丽（ORCID: 0000-0001-6094-5776）,博士,主治医师。" ]
  [ "徐近,主任医师,教授,博士研究生导师。复旦大学附属肿瘤医院胰腺外科主任,上海市抗癌协会神经内分泌肿瘤专业委员会主任委员,中国抗癌协会青年理事会理事,中国抗癌协会胰腺癌专业委员会青委会副主任委员。长期致力于改进胰肠吻合降低胰瘘发生的研究、胰腺癌个体化精准治疗的研究及胰腺神经内分泌肿瘤的综合治疗研究。获得4项国家自然科学基金及多项上海市级课题,以第一或通信讯作者在SCI收录期刊上发表论文30余篇,并荣获上海市职工优秀创新成果一等奖、上海市优秀发明金奖、上海市医学科技奖三等奖。" ]
  [ "虞先濬,主任医师,教授,博士研究生导师,复旦大学附属肿瘤医院副院长,上海市胰腺肿瘤研究所所长,复旦大学胰腺肿瘤研究所所长。国家杰出青年科学基金获得者,国家科技部“中青年科技创新领军人才”,国家百千万人才工程“有突出贡献中青年专家”,全国五一劳动奖章获得者,上海市领军人才,上海工匠,复旦大学首届“名医工程”入选者,中国抗癌协会胰腺癌专业委员会候任主任委员,中国胰腺癌多学科协作组组长,中华医学会外科学分会胰腺外科学组委员,中国医师协会胰腺病专业委员会委员,中国临床肿瘤学会胰腺癌专家委员会常务委员,美国外科医师学会会员。主持国家自然基金中德国际重点合作项目1项、国家自然科学基金面上项目3项、省部级项目12项,总计获得科研经费3 000余万元。以通信作者在Journal of Clinical Oncology、Gut、Annals of Surgery、Cell Research、Autophagy、Clinical Cancer Research、Cancer Research等国际权威SCI收录期刊上发表论文200余篇。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.09.003
  中图分类号： R735.9
- 收稿：2022-02-15，
  
  修回：2022-06-21，
  
  纸质出版：2022-09-30
- 稿件说明：
移动端阅览
高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022,32(9):772-778.

Heli GAO, Jin XU, Xianjun YU. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021[J]. China Oncology, 2022, 32(9): 772-778.
高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022,32(9):772-778. DOI： 10.19401/j.cnki.1007-3639.2022.09.003.

Heli GAO, Jin XU, Xianjun YU. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021[J]. China Oncology, 2022, 32(9): 772-778. DOI： 10.19401/j.cnki.1007-3639.2022.09.003.

摘要

胰腺神经内分泌肿瘤（pancreatic neuroendocrine neoplasm

PanNEN）发病率低且异质性强

有关PanNEN分子机制的研究逐渐增多

同时PanNEN临床诊断、治疗和预后预测也有新的进展。指南除常规推荐手术、介入治疗等局部治疗

以及生长抑素类似物、靶向治疗等系统治疗外

还存在一些手术问题和药物应用的争议

这些问题和争议也体现了PanNEN诊治过程中的个体化原则和全程管理。本文对2021年PanNEN基础和临床方面的研究进展进行综述。

Abstract

Pancreatic neuroendocrine neoplasm (PanNEN) has a low incidence and strong heterogeneity. Research on molecular mechanism of PanNEN is gradually increasing. At the same time

the updates on clinical diagnosis

treatment and prognosis prediction of PanNEN patients are increasing. In addition to surgery and systemic treatment such as somatostatin analogs and tyrosine kinase inhibitors

there are unsolved problems and questions in the management of PanNEN patients

which emphasizes individualized treatment and multidisciplinary treatment. This article summarized the basic and clinical research progress of PanNEN in 2021.

关键词

Keywords

references

ALI H , PAMARTHY R , VALLABHANENI M , et al . Pancreatic cancer incidence trends in the United States from 2000-2017: analysis of Surveillance, Epidemiology and End Results (SEER) database [J ] . F1000Res , 2021 , 10 : 529 . DOI: 10.12688/f1000research.54390.1 http://doi.org/10.12688/f1000research.54390.1

中国临床肿瘤学会指南工作委员会 . 神经内分泌肿瘤诊疗指南(2021) [M ] . 北京 : 人民卫生出版社 , 2021 .

Guideline Working Committee of Chinese Society of Clinical Oncology . Guidelines for the diagnosis and treatment of neuroendocrine tumors (2021) [M ] . Beijing : People’s Medical Publishing House , 2021 .

MANDAIR D , KHAN M S , LOPES A , et al . Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors [J ] . J Clin Endocrinol Metab , 2020 , 106 ( 3 ): 872 - 882 . DOI: 10.1210/clinem/dgaa822 http://doi.org/10.1210/clinem/dgaa822 https://academic.oup.com/jcem/article/106/3/872/5979548 https://academic.oup.com/jcem/article/106/3/872/5979548

OVERSOE S K , SORENSEN B S , TABAKSBLAT E M , et al . Cell-free DNA and clinical characteristics in patients with small intestinal or pancreatic neuroendocrine tumors [J ] . Neuroendocrinology , 2022 , 112 ( 1 ): 43 - 50 . DOI: 10.1159/000514457 http://doi.org/10.1159/000514457 https://www.karger.com/Article/FullText/514457 https://www.karger.com/Article/FullText/514457

MALCZEWSKA A , WITKOWSKA M , WÓJCIK-GIERTUGA M , et al . Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience [J ] . Neuroendocrinology , 2021 , 111 ( 4 ): 304 - 319 . DOI: 10.1159/000508106 http://doi.org/10.1159/000508106 https://www.karger.com/Article/FullText/508106 https://www.karger.com/Article/FullText/508106

MODLIN I M , KIDD M , FRILLING A , et al . Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost-effective and predicts neuroendocrine tumor recurrence with 94% accuracy [J ] . Ann Surg , 2021 , 274 ( 3 ): 481 - 490 . DOI: 10.1097/SLA.0000000000005026 http://doi.org/10.1097/SLA.0000000000005026 https://journals.lww.com/10.1097/SLA.0000000000005026 https://journals.lww.com/10.1097/SLA.0000000000005026

VAN TREIJEN M J C , VAN DER ZEE D , HEERES B C , et al . Blood molecular genomic analysis predicts the disease course of gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest® [J ] . Neuroendocrinology , 2021 , 111 ( 6 ): 586 - 598 . DOI: 10.1159/000509091 http://doi.org/10.1159/000509091 https://www.karger.com/Article/FullText/509091 https://www.karger.com/Article/FullText/509091

LLOYD R V , OSAMURA R Y , KLOPPEL G , et al . WHO classification of tumours of endocrine organs [M ] . 5th ed. Lyon : IARC WHO Classification of Tumours , 2019 , 10 .

National Comprehensive Cancer Network . Clinical practice guidelines in oncology: neuroendocrine and adrenal tumors (version 2. 2021) [EB/OL ] . [ 2022 - 07 - 25 ] . https://www.nccn.org/guidelines/guidelines-detail?category=1 & #x00026;id=1448 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448 .

UEMURA J , OKANO K , OSHIMA M , et al . Immunohistochemically detected expression of ATRX, TSC2, and PTEN predicts clinical outcomes in patients with grade 1 and 2 pancreatic neuroendocrine tumors [J ] . Ann Surg , 2021 , 274 ( 6 ): e949 - e956 . DOI: 10.1097/SLA.0000000000003624 http://doi.org/10.1097/SLA.0000000000003624 https://journals.lww.com/10.1097/SLA.0000000000003624 https://journals.lww.com/10.1097/SLA.0000000000003624

SCARPA A , CHANG D K , NONES K , et al . Whole-genome landscape of pancreatic neuroendocrine tumours [J ] . Nature , 2017 , 543 ( 7643 ): 65 - 71 . DOI: 10.1038/nature21063 http://doi.org/10.1038/nature21063 http://www.nature.com/articles/nature21063 http://www.nature.com/articles/nature21063

JIAO Y C , SHI C J , EDIL B H , et al . DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors [J ] . Science , 2011 , 331 ( 6021 ): 1199 - 1203 . DOI: 10.1126/science.1200609 http://doi.org/10.1126/science.1200609

DI DOMENICO A , PIPINIKAS C P , MAIRE R S , et al . Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression [J ] . Commun Biol , 2020 , 3 ( 1 ): 740 . DOI: 10.1038/s42003-020-01479-y http://doi.org/10.1038/s42003-020-01479-y

YOUNG K , LAWLOR R T , RAGULAN C , et al . Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours [J ] . Gut , 2021 , 70 ( 10 ): 1904 - 1913 . DOI: 10.1136/gutjnl-2020-321016 http://doi.org/10.1136/gutjnl-2020-321016

VERDE F , GALATOLA R , ROMEO V , et al . Pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1: diagnostic value of different MRI sequences [J ] . Neuroendocrinology , 2021 , 111 ( 7 ): 696 - 704 . DOI: 10.1159/000509647 http://doi.org/10.1159/000509647 https://www.karger.com/Article/FullText/509647 https://www.karger.com/Article/FullText/509647

YOO J , KIM S H , JEON S K , et al . Added value of[ 68 Ga ] Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort [J ] . Eur Radiol , 2021 , 31 ( 10 ): 7734 - 7745 . DOI: 10.1007/s00330-021-07859-0 http://doi.org/10.1007/s00330-021-07859-0 https://doi.org/10.1007/s00330-021-07859-0 https://doi.org/10.1007/s00330-021-07859-0

PAIELLA S , LANDONI L , TEBALDI S , et al . Dual-tracer( 68 Ga-DOTATOC and 18 F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases [J ] . Neuroendocrinology , 2022 , 112 ( 2 ): 143 - 152 . DOI: 10.1159/000514809 http://doi.org/10.1159/000514809 https://www.karger.com/Article/FullText/514809 https://www.karger.com/Article/FullText/514809

VEENSTRA E B , DE GROOT D J A , BROUWERS A H , et al . Comparison of 18 F-DOPA versus 68 Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms [J ] . Clin Nucl Med , 2021 , 46 ( 3 ): 195 - 200 . DOI: 10.1097/RLU.0000000000003447 http://doi.org/10.1097/RLU.0000000000003447 https://journals.lww.com/10.1097/RLU.0000000000003447 https://journals.lww.com/10.1097/RLU.0000000000003447

HSU D , LE S , CHANG A , et al . Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected? [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 4108 . DOI: 10.1200/JCO.2021.39.15_suppl.4108 http://doi.org/10.1200/JCO.2021.39.15_suppl.4108 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4108 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4108

ALTIMARI M , ABAD J , CHAWLA A . The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors [J ] . HPB (Oxford) , 2021 , 23 ( 10 ): 1533 - 1540 . DOI: 10.1016/j.hpb.2021.03.005 http://doi.org/10.1016/j.hpb.2021.03.005 https://linkinghub.elsevier.com/retrieve/pii/S1365182X21000721 https://linkinghub.elsevier.com/retrieve/pii/S1365182X21000721

SAHARA K , TSILIMIGRAS D I , MORO A , et al . Long-term outcomes after spleen-preserving distal pancreatectomy for pancreatic neuroendocrine tumors: results from the US neuroendocrine study group [J ] . Neuroendocrinology , 2021 , 111 ( 1/2 ): 129 - 138 . DOI: 10.1159/000506399 http://doi.org/10.1159/000506399 https://www.karger.com/Article/FullText/506399 https://www.karger.com/Article/FullText/506399

ASANO D , KUDO A , AKAHOSHI K , et al . Curative surgery and Ki-67 value rather than tumor differentiation predict the survival of patients with high-grade neuroendocrine neoplasms [J ] . Ann Surg , 2020 , 276 ( 2 ): e108 -e113. DOI: 10.1097/SLA.0000000000004495 http://doi.org/10.1097/SLA.0000000000004495 https://journals.lww.com/10.1097/SLA.0000000000004495 https://journals.lww.com/10.1097/SLA.0000000000004495

张中国抗癌协会胰腺癌专业委员会 . 中国胰腺癌综合诊治指南(2020版) [J ] . 中华外科杂志 , 2021 , 59 ( 2 ): 81 - 100 .

Pancreatic Cancer Committee of Chinese Anti-Cancer Association . Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2020 version) [J ] . Chin J Surg , 2021 , 59 ( 2 ): 81 - 100 .

TITAN A L , NORTON J A , FISHER A T , et al . Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors [J ] . JAMA Netw Open , 2020 , 3 ( 11 ): e2024318.

PARGHANE R V , BHANDARE M , CHAUDHARI V , et al . Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177 Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors [J ] . J Nucl Med , 2021 , 62 ( 11 ): 1558 - 1563 . DOI: 10.2967/jnumed.120.258772 http://doi.org/10.2967/jnumed.120.258772 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.258772 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.258772

GAO H L , LIU L , WANG W Q , et al . Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor [J ] . Cancer Lett , 2018 , 412 : 188 - 193 . DOI: S0304-3835(17)30673-0 http://doi.org/S0304-3835(17)30673-0

WANG W Q , ZHANG W H , GAO H L , et al . A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors [J ] . J Gastroenterol , 2021 , 56 ( 4 ): 395 - 405 . DOI: 10.1007/s00535-021-01777-0 http://doi.org/10.1007/s00535-021-01777-0 https://doi.org/10.1007/s00535-021-01777-0 https://doi.org/10.1007/s00535-021-01777-0

HEIDSMA C M , VAN ROESSEL S , VAN DIEREN S , et al . International validation of a nomogram to predict recurrence after resection of grade 1 and 2 nonfunctioning pancreatic neuroendocrine tumors [J ] . Neuroendocrinology , 2022 , 112 ( 6 ): 571 - 579 . DOI: 10.1159/000518757 http://doi.org/10.1159/000518757 https://www.karger.com/Article/FullText/518757 https://www.karger.com/Article/FullText/518757

PULVIRENTI A , JAVED A A , LANDONI L , et al . Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors [J ] . Ann Surg , 2021 , 274 ( 6 ): 1051 - 1057 . DOI: 10.1097/SLA.0000000000003579 http://doi.org/10.1097/SLA.0000000000003579 https://journals.lww.com/10.1097/SLA.0000000000003579 https://journals.lww.com/10.1097/SLA.0000000000003579

KULKARNI R , KABIR I , HODSON J , et al . Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: a systematic review and meta-analysis [J ] . Ann Hepatobiliary Pancreat Surg , 2022 , 26 ( 1 ): 31 - 39 . DOI: 10.14701/ahbps.21-101 http://doi.org/10.14701/ahbps.21-101 http://www.ahbps.org/journal/view.html?doi=10.14701/ahbps.21-101 http://www.ahbps.org/journal/view.html?doi=10.14701/ahbps.21-101

TSILIMIGRAS D I , HYER J M , PAREDES A Z , et al . Resection of primary gastrointestinal neuroendocrine tumor among patients with non-resected metastases is associated with improved survival: a SEER-medicare analysis [J ] . J Gastrointest Surg , 2021 , 25 ( 9 ): 2368 - 2376 . DOI: 10.1007/s11605-020-04898-8 http://doi.org/10.1007/s11605-020-04898-8

KAEMMERER D , TWRZNIK M , KULKARNI H R , et al . Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms [J ] . Ann Surg , 2021 , 274 ( 1 ): e45 -e53. DOI: 10.1097/SLA.0000000000003237 http://doi.org/10.1097/SLA.0000000000003237

MEROLA E , FALCONI M , RINKE A , et al . Radical intended surgery for highly selected stage Ⅳ neuroendocrine neoplasms G3 [J ] . Am J Surg , 2020 , 220 ( 2 ): 284 - 289 . DOI: 10.1016/j.amjsurg.2020.03.009 http://doi.org/10.1016/j.amjsurg.2020.03.009 https://linkinghub.elsevier.com/retrieve/pii/S0002961020301513 https://linkinghub.elsevier.com/retrieve/pii/S0002961020301513

JANSON E T , KNIGGE U , DAM G , et al . Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms [J ] . Acta Oncol , 2021 , 60 ( 7 ): 931 - 941 . DOI: 10.1080/0284186X.2021.1921262 http://doi.org/10.1080/0284186X.2021.1921262 https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1921262 https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1921262

AL-TOUBAH T , MORSE B , PELLE E , et al . Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide [J ] . Oncologist , 2021 , 26 ( 2 ): 115 - 119 . DOI: 10.1002/onco.13611 http://doi.org/10.1002/onco.13611 https://academic.oup.com/oncolo/article/26/2/115/6445360 https://academic.oup.com/oncolo/article/26/2/115/6445360

LACOMBE C , PERRIER M , HENTIC O , et al . FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors [J ] . Ann Oncol , 2021 , 32 : S621 .

DE RYCKE O , WALTER T , PERRIER M , et al . Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors [J ] . Endocr Relat Cancer , 2021 , 28 ( 7 ): 457 - 466 . DOI: 10.1530/ERC-21-0034 http://doi.org/10.1530/ERC-21-0034 https://erc.bioscientifica.com/view/journals/erc/28/7/ERC-21-0034.xml https://erc.bioscientifica.com/view/journals/erc/28/7/ERC-21-0034.xml

MCGARRAH P W , HOBDAY T J , STARR J S , et al . Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs) [J ] . J Clin Oncol , 2020 , 38 ( 4_suppl ): 617 .

LEPAGE C , PHELIP J M , LIÈVRE A , et al . Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial [J ] . Ann Oncol , 2020 , 31 : S774 .

DEHEZ M , BRENDEL K , SARR C , et al . CLARINET FORTE: characterization of pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with lanreotide autogel (LAN) 120 mg every 14 days (q14d) [C ] . 18th Annual ENETS Conference , 2021 .

PAVEL M , ĆWIKŁA J B , LOMBARD-BOHAS C , et al . Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results [J ] . Eur J Cancer , 2021 , 157 : 403 - 414 . DOI: 10.1016/j.ejca.2021.06.056 http://doi.org/10.1016/j.ejca.2021.06.056

XU J M , SHEN L , BAI C M , et al . Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1489 - 1499 . DOI: 10.1016/S1470-2045(20)30493-9 http://doi.org/10.1016/S1470-2045(20)30493-9

CAPDEVILA J , FAZIO N , LOPEZ C , et al . Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase Ⅱ TALENT trial (GETNE1509) [J ] . J Clin Oncol , 2021 , 39 ( 20 ): 2304 - 2312 . DOI: 10.1200/JCO.20.03368 http://doi.org/10.1200/JCO.20.03368 https://ascopubs.org/doi/10.1200/JCO.20.03368 https://ascopubs.org/doi/10.1200/JCO.20.03368

CLEMENT D , NAVALKISSOOR S , SRIRAJASKANTHAN R , et al . Efficacy and safety of 177 Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 4116 . DOI: 10.1200/JCO.2021.39.15_suppl.4116 http://doi.org/10.1200/JCO.2021.39.15_suppl.4116 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4116 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4116

COFFMAN K L , BODEI L S , LE T , et al . Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177 Lu-DOTATATE [J ] . J Clin Oncol , 2021 , 39 ( 3_suppl ): 368 . DOI: 10.1200/JCO.2021.39.3_suppl.368 http://doi.org/10.1200/JCO.2021.39.3_suppl.368 https://ascopubs.org/doi/10.1200/JCO.2021.39.3_suppl.368 https://ascopubs.org/doi/10.1200/JCO.2021.39.3_suppl.368

RINKE A , AUERNHAMMER C J , BODEI L S , et al . Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? [J ] . Gut , 2021 , 70 ( 9 ): 1768 - 1781 . DOI: 10.1136/gutjnl-2020-321300 http://doi.org/10.1136/gutjnl-2020-321300

GRANDE E , RODRIGUEZ-ANTONA C , LÓPEZ C , et al . Sunitinib and evofosfamide (TH-302) in systemic treatment-naïve patients with grade 1/2 metastatic pancreatic neuroendocrine tumors: the GETNE-1408 trial [J ] . Oncologist , 2021 , 26 ( 11 ): 941 - 949 . DOI: 10.1002/onco.13885 http://doi.org/10.1002/onco.13885 https://academic.oup.com/oncolo/article/26/11/941/6508763 https://academic.oup.com/oncolo/article/26/11/941/6508763

CORTI F , AMOROSO V , CAMPANA D , et al . Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): the phase Ⅱ LOLA trial [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): TPS4167.

STROSBERG J , MIZUNO N , DOI T , et al . Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study [J ] . Clin Cancer Res , 2020 , 26 ( 9 ): 2124 - 2130 . DOI: 10.1158/1078-0432.CCR-19-3014 http://doi.org/10.1158/1078-0432.CCR-19-3014 https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously

HERNANDO J , MANZANO J L , TEULE A , et al . Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: results from the phase Ⅱ DUNE trial (GETNE 1601) [J ] . Ann Oncol , 2021 , 32 : S909 - S910 . DOI: 10.1016/j.annonc.2021.08.181 http://doi.org/10.1016/j.annonc.2021.08.181 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023954 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023954

MANDRIANI B , PELLE E , MANNAVOLA F , et al . Development of CAR T-cells for future treatment of NETs [J ] . Ann Oncol , 2021 , 32 : S911 .

BUTT B P , STOKMO H L , LADEKARL M , et al . Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas [J ] . Ann Oncol , 2021 , 32 : S915 .

RIESCO-MARTINEZ M C , CAPDEVILA J , ALONSO V , et al . Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913) [J ] . Ann Oncol , 2021 , 32 : S908 - S909 . DOI: 10.1016/j.annonc.2021.08.180 http://doi.org/10.1016/j.annonc.2021.08.180 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942

SHEN L , YU X J , LU M , et al . Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: results from a multicenter, open-label, single-arm, phase Ⅱ trial [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): e16199.

浏览量

3419

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

肢端型黑色素瘤组织中MITF的表达及其与临床、病理学特征及预后的相关性研究

人工智能在胃癌诊疗和患者预后预测中的应用现状及未来展望

261例局限期食管小细胞癌患者的临床、预后及治疗模式分析

中国抗癌协会神经内分泌肿瘤诊治指南（2025年版）